Articles from BioIVT

BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced the appointment of Dr. Auro Nair as the company’s Chief Executive Officer. Dr. Nair has served on BioIVT’s Board of Directors since June 2024.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the acquisition of BeCytes Biotechnologies, a Barcelona, Spain-based company specializing in the coordination of the collection, processing and distribution of high-quality human tissues and cells for biomedical research. This marks BioIVT’s continued strategy to expand in key business units supporting NAMs and absorption, distribution, metabolism and excretion (ADME) areas.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will showcase its broad portfolio of cellular solutions at several leading industry events focused on cell and gene therapy innovation, including the 2025 Cell & Gene Meeting on the Mesa.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host “Elevating Drug Development with NAMs: Meeting the FDA’s Call for Change,” a complimentary symposium on Oct. 22, 2025 in San Diego. BioIVT will host a panel of industry experts at The Alexandria at Torrey Pines in San Diego during the event for a series of presentations and discussions around the development, validation, and utilization of NAMs for a variety of ADME-Tox applications. Please visit BioIVT’s website for registration and additional details here.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced a company milestone with a new office space, including a state-of-the-art laboratory in Woodbury, New York. This expansion supports the company’s continued commitment to enabling life-saving research within New York's booming research community and beyond.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the opening of its Hepatocyte Grants Program and that it is actively reviewing research proposals. As a leader in the field, BioIVT is committed to supporting groundbreaking research by providing free access to select lots of the company’s highly characterized cryosuspension hepatocytes that are ideally suited to non-CYP metabolism studies and other novel applications.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today introduced Visionaire™ to support researchers in addressing data reproducibility, scalability, and accessibility challenges that arise when applying artificial intelligence (AI) in target discovery, drug development, and digital pathology. With over 40 years of experience in biospecimen procurement to bring the best products to researchers in need, Visionaire is BioIVT’s latest innovation to transform data into actionable insights, further fueling life-saving medical discoveries.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced a complimentary neuroscience symposium in South San Francisco, California, on June 25, 2025. The event ‘Advancing Neuroscience: Breakthroughs in Biomarker Discovery and Preclinical Development for Neurological Diseases’ will bring together the brightest minds in the industry to explore developments in neuroscience and biomarkers. The gathering is the company’s latest effort to enable smarter science and accelerate medical advancements in the industry.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced an exclusive commercial agreement with Handok Biotech Co. LTD., which will allow Handok to offer researchers in South Korea access to a wider range of high-quality, innovative products. The strategic alliance provides unparalleled opportunities for researchers, ultimately, elevating life science research in Asia.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the launch of VivoSTART™ Cryopreserved GMP Leukopaks. The GMP-compliant leukopaks ensure the quality, safety, and traceability of cellular starting material to support cell and gene therapy (CGT) platform process development and clinical trials. The addition to the company’s portfolio of human derived cellular starting materials emphasizes the commitment to supporting cell therapy development.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, presented new data at the Precision Med TRI-CON conference. The data supports an innovative protocol for replicating fine needle aspirations (FNAs) in a laboratory setting using fresh frozen tissue samples. Preliminary results demonstrate the method’s promise for accurate molecular annotation and highlight its potential to revolutionize approaches to companion diagnostics development.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today launched LEUKOMAX XL, a new leukopak product that provides researchers with a minimum of 15 billion TNC. LEUKOMAX XL features the most cells from a single donor collection per volume, including over 50% more cells per bag than the standard Leukopak Full Paks, and is available through U.S. and U.K. collection sites.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will attend and sponsor the 8th Annual Biomarker & Precision Medicine U.S. Congress (Biomarkers U.S. 2024) and exhibit at The Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024) where the company will feature its new Ki67 tissue staining service to support ADC development.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will have a significant presence at the 2024 Cell and Gene Meeting on the Mesa, taking place from Oct. 7-9, 2024, in Phoenix. As a premier sponsor, BioIVT will be at booth #F12 and will showcase how its expansive portfolio of cellular solutions and ancillary materials are supported by its large, highly characterized, recallable network of donors at the conference. Additionally, Lisa Kretzschmar, Senior Scientific Advisor for Cell & Gene Therapy at BioIVT will be a featured panelist on the discussion: “Exploring Manufacturing Strategies: Decentralized vs. Centralized Approaches in Cell and Gene Therapies.” The panel will take place on Monday, Oct. 7 at 5pm MST in FLW Ballroom E.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will be attending and sponsoring leading industry and philanthropic events focused on cell and gene therapy research, developments and breakthroughs.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Trending Topics in ADME & Drug Development Research, a complimentary symposium on Nov. 6, 2024, at the Mass Bio Hub in Cambridge, Massachusetts, to discuss novel in vitro ADME research methodologies that may be incorporated into preclinical programs to guide lead selection and optimization and improve IVIVC. Featuring researchers from academia, industry and BioIVT, the symposium will also highlight the new ICH M12 regulatory guidance and present recently published studies and other data on how complex models are being used to investigate the ADME-Tox properties of new drugs. Please visit BioIVT’s website for registration and additional details here.